drugset
Drugs / autologous bone marrow concentrate
last change May 2021 re-read 9 days ago

autologous bone marrow concentrate

also known as aBMC · BMC

Cell therapy

Developed for
bone marrow disorder · limb ischemia · osteoarthritis, knee
Investigated by
Rizzoli Orthopaedic Institute · Cesca Therapeutics, Inc.

Trials 3

today NCT02538978 · Ph 3 NCT03110679 · Ph 4 NCT03112122 · Ph 4
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT02538978 Jan 2017 → Dec 2018 limb ischemia Cesca Therapeutics, Inc. Unknown No outcome recorded
Phase 42 trials
Phase 4 NCT03110679 May → Nov 2016 osteoarthritis, knee Rizzoli Orthopaedic Institute Completed No outcome recorded
Phase 4 NCT03112122 Mar 2016 → Dec 2017 bone marrow disorder Rizzoli Orthopaedic Institute Terminated No outcome recorded Stop: Enrollment

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as autologous bone marrow concentrate ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110679 ↗
2

NCT03112122 ↗

NCT02538978 ↗
Known as aBMC “Autologous Bone Marrow Concentrate (aBMC)” NCT02538978 ↗
Known as BMC “injections of autologous Bone Marrow Concentrate (BMC)” NCT03112122 ↗
Modality Cell therapy “autologous bone marrow cell concentrate (aBMC) into the afflicted lower index limb” NCT02538978 ↗
Route Intramuscular “intramuscular injection of autologous bone marrow concentrate (aBMC)” NCT02538978 ↗